The comparative characteristic of lymphocytes subpopulations and their ratios in sites of partial spontaneous regression and in a peritumoralny lymphocytic infiltration in primary skin melanoma
DOI: 10.22138/2500-0918-2017-14-1-40-48
Y. A. Bozhchenco, Y. V. Vishnevskaya, I. A. Pokataev, L. V. Demidov
N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
Abstract. The ability of skin melanoma (SM) to regress, or progression, is largely due to the interaction of tumor cells and the local immunity system. Aim. Study of the subpopulations of lymphocytes with the calculation of their absolute mean values and ratios in the lymphoid infiltrate in the areas of partial spontaneous regression of the primary melanoma of the skin (PSM) and in the area of peritumoral lymphocytic tumor infiltration (PLTI). Materials andmethods. Histological material from 277 patients with MK carried out immunohistochemical studies of subpopulations of CD45, CD3, CD8, CD4, CD20, FoxP3 lymphocytes in the lymphoid infiltrate in the sites of partial spontaneous regression of PSM and in the areas of PLTI. Results. In the region of partial spontaneous regression, the absolute mean values of such subpopulations of lymphocytes as CD45, CD3, and CD8 were higher in comparison with PLTI. In the regions of regression of PSM and PLTI sites in patients with no progression of the disease, a higher ratio of CD8/FoxP3 and CD4/FoxP3 T-lymphocytes was observed, compared to the sites of PLTI in patients with progression of the disease. At that, the ratio of CD8/CD4 T lymphocytes was almost the same both in the regions of regression of PSM, and in the regions of the PLTI. Conclusion. The obtained data of absolute and average values of the subpopulations of immune cells and their ratios are of great clinical importance and can be used further for immunocorrection in prognostically unfavorable observation groups.
Keywords: skin melanoma, tumor regression, tumor-infiltration lymphosytes, CD8+, CD4+, T-lymphocytes
Received 28.02.2017
For citation:
Bozhchenco Y.A., Vishnevskaya Y.V., Pokataev I.A., Demidov L.V. The comparative characteristic of lymphocytes subpopulations and their ratios in sites of partial spontaneous regression and in a peritumoralny lymphocytic infiltration in primary skin melanoma. Vestn. Ural. Med. Akad. Nauki. Journal of Ural Medical Academic Science. 2017, Vol. 14, no. 1, pp. 40–48. DOI: 10.22138/2500-0918-2017-14-1-40-48 [In Russ.]
REFERENCES
1. Zurac S., Negroiu G., Petrescu S., Andrei R., Tebeica T., Popp C., Mustata R. Spectrum of morphologic alterations of regression in cutaneous melanoma — potential for improving disease prognosis. Rom J. Intern. Med. 2012; 50(2):145-53.
2. Cintolo J.A., Gimotty P., Blair A., Guerry D., Elder D.E., Hammond R., Elenitsas R., Xu X., Fraker D., Schuchter L.M., Czerniecki B.J., Karakousis G. Local immune response predicts survival in patients with thick (t4) melanomas. Ann. Surg. Oncol. 2013; 20(11):3610-7. DOI: 10.1245/s10434-013-3086-3.
3. Maurichi A., Miceli R., Camerini T., Mariani L., Patuzzo R., Ruggeri R., Gallino G. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J. Clin. Oncol. 2014; 32(23): 2479-85. DOI: 10.1200/JCO.2013.54.2340.
4. Martires K.J., Barnholtz-Sloan J.S., Bordeaux J.S.A call for consistent reporting of regression in melanoma. Arch. Dermatol. 2012;148(9):1081-3. DOI: 10.1001.
5. Ribero S., Osella-Abate S., Sanlorenzo M., Savoia P., Astrua C., Cavaliere G., Tomasini C., Senetta R., Macripo G., Bernengo M.G., Quaglino P. Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. Br. J. Dermatol. 2013;169(6):1240-5. DOI: 10.1111.
6. Tas F., Erturk K. Presence of histological regression as a prognostic factor in cutaneous melanoma patients. Melanoma Res. 2016 Jul 1. [Epub ahead of print]. DOI:10.1097/CMR.0000000000000277
7. Burton A.L., Gilbert J., Farmer R.W., Stromberg A.J., Hagendoorn L., Ross M.I., Martin R.C., McMasters K.M., Scoggins C.R., Callender G.G. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Am Surg. 2011;77(8):1009-13.
8. Botella-Estrada R., Traves V., Requena C., Guillen-Barona C., Nagore E. Correlation of histologic regression in primary melanoma with sentinel node status. JAMA Dermatol. 2014;150(8):828-35. DOI: 10.1001/jamadermatol.2013.9856
9. Hussein M.R., Elsers D.A., Fadel S.A., Omar M.A. Immunohistologicalcharacterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J ClinPathol. 2006; 59(3): 316–324.
10. Ribero S., Moscarella E., Ferrara G., Piana S., Argenziano G., Longo C. Regression in cutaneous melanoma: a comprehensive review from diagnosis to prognosis. J. Eur. Acad. Dermatol. Venereol. 2016; 12. DOI: 10.1111/jdv.13815. [Epub ahead of print].
11. McClain S.E., Shada A.L., Barry M., Patterson J.W., Slingluff C.L. Jr. Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. Melanoma Res. 2012; 22(4):302-9. DOI: 10.1097/CMR.0b013e328353e673.
12. Botella-Estrada R., Kutzner H. Study of the Immunophenotype of the Inflammatory Cells in Melanomas With Regression and Halo Nevi. Am. J. Dermatopathol. 2015; 37:376–380. DOI: 10.1097/DAD.0000000000000205.
Authors
Yana A. Bozhchenko
Post-graduate student, Pathologist of Department of Pathological Anatomy of Human Tumors
Laody.1981@mail.ru
Yana V. Vishnevskaya
Cand. Sci. (Med.), Senior Researcher, Pathologist Department of Pathological Anatomy of Human Tumors
yana_vishn@list.ru
Ilya A.Pokataev
Cand. Sci. (Med.), Doctor Chemotherapist Department of Clinical Pharmacology and Chemotherapy
pokia@mail.ru
Lev V. Demidov
Dr. Sci. (Med.), Professor, Head of Department of Biotherapy of Tumor
demidov.lev@gmail.com
N.N Blokhin Russian Cancer Research Center
Kashirskoye sh., 23, Moscow, Russian Federation, 115478
